Lantern Pharma Inc. - Common Stock (NQ:LTRN)

Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering

September 30, 2026

InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Announces $4 Million Registered Direct Offering

Performance

52-Week Range 81.7% below 52-week high

0.8601

0.9752W Low 4.7052W High

1 Week 32.8% below 1-week high

0.971W Low 1.281W High

Lantern Pharma Inc. - Common Stock (LTRN) traded between $0.97 and $4.70 over the past 52 weeks and last traded at $0.86, 81.7% below its 52-week high. Over the past week it ranged between $0.97 and $1.28.

Past 12 Months

-29.5%

-57.4%

-78.3%

-46.9%

-72.3%

-79.1%

1W -$0.36

1M -$1.16

3M -$3.11

6M -$0.76

YTD -$2.25

1Y -$3.26

LTRN was -79.1% over the past year, -46.9% over six months, -72.3% year to date, -29.5% in the last week.

12 Months vs Market

LTRN

-79.1%

DIA

+10.1%

SPY

+15.1%

QQQ

+24.3%

IWM

+16.1%

Over the past 12 months LTRN returned -79.1% versus DIA (Dow) +10.1%, SPY (S&P 500) +15.1%, QQQ (Nasdaq 100) +24.3% and IWM (Russell 2000) +16.1%.

Volume & Liquidity 2.47× 3-mo avg

Today 432,577 3-mo avg 174.8K

344.0K

274.4K

174.8K

228.3K

YTD

314.0K

259.4K

LTRN most recently traded 432,577 shares against a 3-month average daily volume of 174.8K.

More News

September 29, 2026

Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering

September 29, 2026

New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global

September 26, 2026

AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present Open-Medicine AI Growth Plan, Live Platform Demo in Webinar

September 23, 2026

Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET

September 23, 2026

MissionIRNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives USPTO Notice of Allowance for LP-284 Blood Cancer Treatment Patent

September 22, 2026

Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas

September 22, 2026

New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global

September 19, 2026

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) to Host Webinar on Open-Medicine AI Platform, Business Model and Development Roadmap

September 17, 2026

Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23

September 17, 2026

New to The Street Show 771 Airs Today on Bloomberg, Featuring Bill Mobley, Panna Sharma, Phillip Toppino and Dr. Kelley Gurley

September 12, 2026

New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC) and FreeCast (NASDAQ:CAST)

September 05, 2026

New to The Street Broadcasting Today at 6:30 PM EST on Bloomberg Television Across the U.S., Latin America and MENA-Featuring FreeCast (NASDAQ: CAST), Metaterra Holdings (MTHI) and SafeSpace Global (SGCC)

August 29, 2026

NetworkNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Advances AI-Driven Oncology Pipeline, Establishes Open Medicine AI

Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript ↗

August 21, 2026

Via The Motley Fool

August 14, 2026

Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update

August 14, 2026

New to The Street Show 766 Broadcasts Tonight at 6:30 PM ET on Bloomberg Television, Featuring BioVie's Bezisterim Parkinson's Disease Clinical Results

August 08, 2026

InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Schedules Second-Quarter 2026 Results Webcast

August 07, 2026

Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET

August 07, 2026

Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine

August 03, 2026

New to The Street TV Announces Broadcast of Show No. 765 Tonight on Bloomberg Television at 6:30 PM ET Featuring Envoy Medical, Graphene Manufacturing Group, Rhino Bitcoin, and Big Sky Industrial

August 01, 2026

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) EMA Clears LP-184 Bladder Cancer Trial in Europe

July 28, 2026

Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer

July 28, 2026